Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

HER2+ Breast Cancer

SEA-22-OSD1249 - /clinical/her2-positive-neoadjuvant-care

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Special Reports in Personalized Cancer Care

The OncLive Special Reports in Personalized Cancer Care condition center is a comprehensive resource for clinical news and expert insights on personalized  treatment in lung cancer, breast cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, gynecologic cancers, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research as it relates to precision oncology therapeutics. 

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer. 


Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer